Stockholders' Equity (Tables)
|
3 Months Ended |
Mar. 31, 2026 |
|---|
| Stockholders Equity Note [Abstract] |
|
| Schedule of Common Stock Reserved for Future Issuance |
The Company had reserved shares of common stock for future issuance as shown in the table below:
|
|
|
|
|
|
|
|
|
|
|
March 31,
2026 |
|
|
December 31,
2025 |
|
Shares of common stock reserved for future issuance upon exercise of outstanding warrants and pre-funded warrants |
|
|
19,100,800 |
|
|
|
19,100,800 |
|
Shares of common stock reserved for future issuance upon exercise under the 2019 Stock Incentive Plan |
|
|
11,763,268 |
|
|
|
9,023,200 |
|
Shares of common stock reserved for future issuance under the 2019 Employee Stock Purchase Plan |
|
|
1,103,842 |
|
|
|
1,103,842 |
|
Shares of common stock reserved for future issuance upon exercise under the 2012 Stock Incentive Plan |
|
|
278,418 |
|
|
|
278,418 |
|
|
|
|
32,246,328 |
|
|
|
29,506,260 |
|
|
| Warrant Activity Including Activity Related To Pre-funded Warrants |
Warrants Warrant activity, including activity related to pre-funded warrants, is shown in the table below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of
Pre-funded Warrant
Shares |
|
|
Number of
Common Stock Warrant
Shares |
|
|
Total Number of
Warrant
Shares |
|
|
Weighted
Average
Exercise
Price |
|
Outstanding as of December 31, 2025 |
|
|
17,248,948 |
|
|
|
1,851,852 |
|
|
|
19,100,800 |
|
|
$ |
0.13 |
|
Exercised |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
$ |
— |
|
Outstanding as of March 31, 2026 |
|
|
17,248,948 |
|
|
|
1,851,852 |
|
|
|
19,100,800 |
|
|
$ |
0.13 |
|
|
| Schedule of Share-based Compensation, Stock Options, Activity |
A summary of the Company’s combined stock option activity for the 2019 Plan and the 2012 Plan is as follows:
|
|
|
|
|
|
|
|
|
|
|
Number of
Option
Shares |
|
|
Weighted
Average
Exercise
Price |
|
|
|
|
|
|
|
|
Outstanding as of December 31, 2025 |
|
|
9,301,618 |
|
|
$ |
3.63 |
|
Granted |
|
|
3,176,250 |
|
|
$ |
10.66 |
|
Exercised |
|
|
(104,992 |
) |
|
$ |
2.11 |
|
Forfeited |
|
|
(331,190 |
) |
|
$ |
6.74 |
|
Expired |
|
|
— |
|
|
$ |
— |
|
Outstanding as of March 31, 2026 |
|
|
12,041,686 |
|
|
$ |
5.41 |
|
Options exercisable as of March 31, 2026 |
|
|
5,918,559 |
|
|
$ |
3.46 |
|
Options unvested as of March 31, 2026 |
|
|
6,123,127 |
|
|
$ |
7.29 |
|
|
| Schedule of Stock-based Compensation Expenses Recognized |
The following table summarizes the classifications of stock-based compensation expenses for the 2012 Plan, the 2019 Plan and the 2019 ESPP recognized in the Condensed Consolidated Statements of Comprehensive Loss:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
March 31, |
|
|
|
2026 |
|
|
2025 |
|
General and administrative expense |
|
$ |
1,349 |
|
|
$ |
682 |
|
Research and development expense |
|
|
842 |
|
|
|
526 |
|
Total stock-based compensation expenses |
|
$ |
2,191 |
|
|
$ |
1,208 |
|
|